Fragility fracture risk increased with age and decreased with higher BMD in patients with type 1 diabetes.
Researchers evaluated trabecular bone scores in 114 women during either "legs up" or "legs down" dual energy x-ray absorptiometry scans.
The Bone Health TeleECHO Clinic helps mentor healthcare professionals and improves osteoporosis care in underserved communities.
Dual-energy X-ray absorptiometry for bone age assessment complements traditional radiologic assessment.
This week, a phase III trial for investigational drug voclosporin for lupus nephritis treatment was approved, prolonged insomnia may lead to less robust bone formation — causing osteoporosis and bone fractures — and researchers found that women who drink a moderate amount of alcohol daily have a reduced risk of developing systemic lupus erythmatosus.
Three-year fracture study examines the effects of osteoporosis drug denosumab on fractures, bone mineral density, and bone turnover markers in postmenopausal women with osteoporosis.
Prospective observational cohort study examines association between post-ICU administration of anti-fracture therapy or glucocorticoids and longitudinal changes in bone mineral density.
For postmenopausal women with type 2 diabetes mellitus, the correlation between bone and basal metabolism depends on serum 25-hyroxyvitamin D levels.
Study used the University of Utah Health Care electronic health record (EHR) database, which contained data from 1.6 million patients.
WCO 2017, FDA grants Rituxan Breakthrough Therapy status, and a close-up of pediatric Sjögren's syndrome highlight this week's The Handoff.
Testosterone treatments help improve volumetric bone mineral density and bone strength in elderly men with low testosterone.
Observational study examines use of osteoporosis-related assessments and treatment in women who experienced their first hip fracture.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
A retrospective study examined the risk of developing fractures in postmenopausal women with osteoporosis who discontinued bisphosphonate therapy.
Low serum levels of dehydroepiandrosterone, DHEA, and it's sulfate (DHEAS) in older men are markers for osteoporotic fracture risk, researchers say.
Long-term tenofovir treatment for hepatitis B infection is linked with abnormal phosphorus metabolism in a recent study.
Study analyzed data on 1.6 million Americans with osteoporosis aged 65 and older.
Data comes from a multicenter randomized trial involving 1,111 femoral neck fracture patients who took vitamin D after surgery.
Juvenile idiopathic arthritis highlights this week's edition, plus other news in the world of rheumatic disease.
Study co-investigator says most recent clinical practice guidelines provide treatment recommendation that is "not based on the evidence" but instead represents "unsubstantiated opinion."
Bisphosphonate treatment for osteoporosis among women older than 65 goes up after 2008 recommendations.
Study investigators suggest clinicians consider more aggressive preventive therapy for cardiovascular disease in patients with rheumatoid arthritis who have experienced a fragility fracture.
The International Osteoporosis Foundation and European Calcified Tissue Society Working Group proposed a screening strategy measuring certain bone turnover markers in patients who have initiated oral bisphosphonate therapy for postmenopausal osteoporosis as a practical way to identify low adherence.
High-inflammation diets were associated with greater bone density loss in a recent observational study.
Research shows that younger survivors are at increased risk of serious long-term health conditions resulting from thyroid cancer treatments.
A population-based cohort study compared patients with psoriatic arthritis, psoriasis, and rheumatoid arthritis with matched comparators to determine fracture risk associated with the conditions.
Finland-based Bone Index announced that the U.S. Food and Drug Administration (FDA) has approved its second-generation Bindex device to aid in diagnosing osteoporosis.
A standardized process for data analysis and internal benchmarking facilitated a reduction in pain following hip arthroplasty.
Cardiovascular disease, stroke, diabetes, hip and knee replacements, and both behavioral and mental disorders were also more common in the AD cohort.
Rheumatology Advisor Articles
- Rheumatoid Arthritis Increases Mortality Risk in Staphylococcus aureus Infections
- First Clinical Practice Guidelines for Sjögren's Syndrome Developed
- Antibiotic Resistance Problem Brought Before Congress
- FDA Delays Approval of JAK Inhibitor Baricitinib
- How Effective is RF Denervation for Symptomatic Knee OA?
- Allopurinol Use In Concomitant Gout and Diabetes Lowers Cardiovascular Event Risk
- Measuring Disease Activity in Psoriatic Arthritis
- JAK/STAT Inhibitors: A New Treatment Target for Rheumatoid Arthritis
- Biosimilar Confidence: Physician-Patient Communication Sets the Tone
- VA and DoD Practice Guideline Update: Opioids for Chronic Pain
- Leg Positioning During Lumbar DXA Does Not Impact Trabecular Bone Scores
- Should Trabecular Bone Score Be Used to Predict Fragility Fracture Risk in T1D?
- DXA for Pediatric Bone Age Assessment Yields Similar Results vs Traditional Radiography
- Remote Osteoporosis Specialist Mentoring Program Improves Physician Self-Confidence
- Increased Costs Associated With Specialists Providing Primary Care